Clinical Trial Update: A Study of KRN23 in X-linked Hypophosphatemia [Phase 1]

View source ↗

Summary

An update on Kyowa Kirin's Phase 1 study of KRN23 for X-linked Hypophosphatemia, noting that the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• X-linked Hypophosphatemia

Drugs mentioned

• KRN23 (burosumab)

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: X-linked Hypophosphatemia | Phase 1 | Status: COMPLETED